Synonyms: NARC-1, neural apoptosis regulated convertase 1
Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | PCSK9 |
|---|---|---|
| PF-06446846 | 0 | |
| PF-06446846 hydrochloride | 0 | |
| SBC-110736 | 0 | |
| R-IMPP | 0 | |
| SBC-115076 | 9 |
| Description |
Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.
|
|---|
| CAS No. | 1245916-14-6 |
|---|---|
| Molecular Weight | 150 kDa |
| Isotype | human IGg1, κ |
| Application | Alirocumab (anti-PCSK9) |
| Source | CHO |
| Purification | Protein G |
| Sterility | 0.2 μM filtered |
| Formulation | PBS Buffer, PH 7.4 |
| Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT07586540 | NOT_YET_RECRUITING | Drug: Alirocumab|Drug: Placebo|Drug: Atorvastatin | Carotid Stenosis | Middle East North Africa Stroke and Interventional Neurotherapies Organization | 2027-07 | PHASE3 |
| NCT07686796 | NOT_YET_RECRUITING | Drug: CAPOX (oxaliplatin/capecitabine)|Drug: Sintilimab|Drug | Local Advanced Rectal Cancer; PD-1 Inhibitor; PCSK9 Inhibitor; RCT; Radiotherapy; Capecitabine; Oxaliplatin | Guangdong Provincial People's Hospital | 2027-01-01 | PHASE3 |
| NCT06385262 | SUSPENDED | Drug: Alirocumab|Drug: Cemiplimab|Drug: Chemotherapy | Non Small Cell Lung Cancer | Duke University | 2025-03-17 | PHASE2 |
| NCT07704918 | RECRUITING | Drug: Statins (atorvastatin, rosuvastatin, simvastatin, or p | Melanoma | University of Colorado, Denver | 2026-12-31 | |
| NCT07581808 | RECRUITING | Drug: Inclisiran|Drug: Alirocumab | Hypercholesterolemia; Atherosclerotic Cardiovascular Disease (ASCVD) | University Medical Centre Ljubljana | 2026-05-18 | PHASE4 |
| NCT04781322 | RECRUITING | Drug: Alirocumab | Alcohol Associated Liver Disease; Heavy Drinking Behavior | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 2021-10-19 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-05-14)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.